Delayed
Nasdaq
20:45:05 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
4.445
USD
|
-0.78%
|
|
-9.84%
|
+4.10%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
598.9
|
355.3
|
216.2
|
230.3
|
-
|
-
|
Enterprise Value (EV)
1 |
333.9
|
89.01
|
216.2
|
230.3
|
230.3
|
230.3
|
P/E ratio
|
-2.06
x
|
-1.31
x
|
-0.97
x
|
-1.47
x
|
-8.89
x
|
31.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11
x
|
3.88
x
|
2.15
x
|
2.63
x
|
2
x
|
2.13
x
|
EV / Revenue
|
11
x
|
3.88
x
|
2.15
x
|
2.63
x
|
2
x
|
2.13
x
|
EV / EBITDA
|
-2.01
x
|
-1.41
x
|
-0.95
x
|
-1.47
x
|
-4.75
x
|
-6.95
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.68
x
|
1.14
x
|
0.82
x
|
1.61
x
|
1.53
x
|
-
|
Nbr of stocks (in thousands)
|
23,369
|
37,917
|
50,625
|
51,405
|
-
|
-
|
Reference price
2 |
25.63
|
9.370
|
4.270
|
4.480
|
4.480
|
4.480
|
Announcement Date
|
22/03/22
|
16/03/23
|
05/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
54.52
|
91.5
|
100.4
|
87.4
|
115.2
|
108.1
|
EBITDA
1 |
-
|
-297.6
|
-251.6
|
-227.3
|
-156.3
|
-48.52
|
-33.13
|
EBIT
1 |
-
|
-313.9
|
-263.1
|
-237.6
|
-165.2
|
-55.15
|
-42.61
|
Operating Margin
|
-
|
-575.82%
|
-287.6%
|
-236.69%
|
-188.99%
|
-47.87%
|
-39.41%
|
Earnings before Tax (EBT)
1 |
-
|
-292.2
|
-254.2
|
-217.6
|
-159.1
|
-61.88
|
-28.89
|
Net income
1 |
-120.1
|
-292.2
|
-254.2
|
-217.6
|
-80.66
|
-19.37
|
7.416
|
Net margin
|
-
|
-535.95%
|
-277.77%
|
-216.73%
|
-92.28%
|
-16.81%
|
6.86%
|
EPS
2 |
-5.000
|
-12.44
|
-7.130
|
-4.420
|
-3.050
|
-0.5037
|
0.1411
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/10/21
|
22/03/22
|
16/03/23
|
05/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
19.26
|
16.03
|
8.429
|
13.48
|
13.41
|
56.18
|
41.62
|
36.05
|
12.03
|
10.68
|
12.44
|
17.37
|
23.34
|
23.19
|
EBITDA
1 |
-60.57
|
-
|
-
|
-
|
-
|
-
|
-
|
-45.75
|
-
|
-56.91
|
-37.29
|
-24.48
|
-14.81
|
-11.27
|
EBIT
1 |
-65.24
|
-68.37
|
-90.59
|
-76.97
|
-68.37
|
-27.21
|
-51.71
|
-47.99
|
-57.3
|
-59.94
|
-51.15
|
-42.37
|
-38.61
|
-33.03
|
Operating Margin
|
-338.78%
|
-426.44%
|
-1,074.72%
|
-570.92%
|
-509.9%
|
-48.44%
|
-124.25%
|
-133.13%
|
-476.13%
|
-560.99%
|
-411.37%
|
-243.86%
|
-165.42%
|
-142.45%
|
Earnings before Tax (EBT)
1 |
-60
|
-60.97
|
-85.71
|
-77.4
|
-67.88
|
-23.14
|
-47.02
|
-42.09
|
-71.64
|
-56.82
|
-52.67
|
-32.64
|
-24.51
|
-19.23
|
Net income
1 |
-60
|
-60.97
|
-85.71
|
-77.42
|
-67.88
|
-23.14
|
-47.02
|
-42.09
|
-71.64
|
-56.82
|
-52.67
|
-25.38
|
-10.4
|
-8.283
|
Net margin
|
-311.58%
|
-380.3%
|
-1,016.86%
|
-574.25%
|
-506.26%
|
-41.2%
|
-112.97%
|
-116.76%
|
-595.3%
|
-531.84%
|
-423.59%
|
-146.07%
|
-44.54%
|
-35.72%
|
EPS
2 |
-
|
-2.550
|
-3.200
|
-2.020
|
-1.760
|
-0.6000
|
-1.080
|
-0.8300
|
-1.400
|
-1.110
|
-1.010
|
-0.5728
|
-0.2001
|
-0.1586
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/12/21
|
22/03/22
|
12/05/22
|
10/08/22
|
07/11/22
|
16/03/23
|
03/05/23
|
14/08/23
|
14/11/23
|
05/03/24
|
08/05/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
265
|
266
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-135%
|
-75.8%
|
-76.9%
|
-41.6%
|
-6.78%
|
-11.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
15.30
|
8.190
|
5.180
|
2.790
|
2.920
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
11.6
|
22.8
|
13.9
|
12.4
|
13
|
-
|
Capex / Sales
|
-
|
21.23%
|
24.97%
|
13.81%
|
14.21%
|
11.32%
|
-
|
Announcement Date
|
08/10/21
|
22/03/22
|
16/03/23
|
05/03/24
|
-
|
-
|
-
|
Last Close Price
4.48
USD Average target price
10.83
USD Spread / Average Target +141.82% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.10% | 230M | | +24.29% | 46.71B | | +48.83% | 41.8B | | -0.98% | 41.52B | | -5.86% | 29.55B | | +11.21% | 25.78B | | -20.89% | 19.26B | | +3.03% | 12.14B | | -2.21% | 12.08B | | +30.69% | 11.98B |
Other Biotechnology & Medical Research
|